Related Experiment Video
Updated: Jul 8, 2025

07:39
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
111
Successful Treatment of Recurrent Pericarditis With Rilonacept in Acute Promyelocytic Leukemia
Mustafa Atar1, Muhammad Majid1,2, Zachary Yaker1
1Center for Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
JACC. Case Reports
|December 14, 2023
Summary
Recurrent pericarditis in acute promyelocytic leukemia patients can be challenging. Interleukin-1 inhibitor rilonacept offers a successful treatment option for refractory cases.
Area of Science:
- Cardiology
- Hematology
- Oncology
Background:
- Acute promyelocytic leukemia (APL) treatment involves all-trans retinoic acid and arsenic trioxide.
- Pericarditis and pericardial effusion are potential complications during APL treatment.
- Refractory cases pose a significant clinical challenge.

